Did Vascepa Cause Nausea or Vomiting in Studies?
Clinical trials for Vascepa (icosapent ethyl) reported low rates of nausea and vomiting. In the pivotal REDUCE-IT trial with over 8,000 high-risk cardiovascular patients, nausea occurred in 4.5% of Vascepa users versus 3.9% on placebo, and vomiting in 1.5% versus 1.1%. These were mild and led to discontinuation in under 0.5% of cases.[1][2]
How Common Are These Side Effects for Patients?
Real-world data aligns with trials: nausea affects about 3-5% of users, often transient and dose-related, resolving within weeks. Vomiting is rarer, under 2%. The label lists both as 'common' but not severe; they're less frequent than with other fish oil products due to Vascepa's purified EPA form.[1][3]
What Should You Do If Nausea Starts?
Take with food to reduce GI upset. If persistent, consult your doctor—may indicate gallbladder issues or interaction with statins. Hydration and anti-nausea meds like ondansetron help short-term. Most resolve without stopping therapy.[2][4]
Who Gets Nausea More Often?
Higher risk with starting high doses (4g/day), history of GI sensitivity, or concurrent fibrates. Women and elderly report slightly more, per post-marketing surveillance.[3][5]
How Does Vascepa Compare to Lovaza or Fish Oil?
Vascepa has fewer GI effects than mixed EPA/DHA products like Lovaza (nausea ~10%) or OTC fish oil (up to 15%), thanks to no DHA, which irritates the gut more.[1][6]
[1]: FDA Vascepa Label
[2]: REDUCE-IT Trial (NEJM)
[3]: Drugs.com Vascepa Side Effects
[4]: Amarin Patient Resources
[5]: FAERS Database Summary
[6]: Lovaza Label Comparison